Coronaviruses (CoVs) are highly prevalent and severe pathogens that cause a wide range of diseases in multiple species of animals, including humans (16, 25, 30, 36) . In 2003, the etiological agent responsible for the global outbreak of a life-threatening atypical pneumonia that caused approximately 800 deaths worldwide was identified as the severe acute respiratory syndrome CoV (SARS-CoV) (7, 9, 14, 15, 24) . A prototype of the Coronaviridae family is avian infectious bronchitis virus (IBV) (16, 30) , which belongs to the genetic group III of CoV (16) and causes considerable economic losses for the poultry industry worldwide (5, 13) .
CoVs are enveloped positive-stranded RNA viruses with the largest viral RNA genomes known to date, ranging from 27 to 31 kb (16) . The CoV replicase gene encodes two overlapping polyproteins, termed pp1a and pp1ab, which mediate viral replication and transcription (3, 16, 29, 36) . The maturation of CoVs involves a highly complex cascade of proteolytic processing events on the polyproteins to control viral gene expression and replication. Most maturation cleavage events within the precursor polyprotein are mediated by the CoV main protease (CoV M pro ; also known as 3CL protease or 3CL pro ), a threedomain (domains I to III) cysteine protease with a chymotrypsin-like two-domain fold at the N terminus (10, 18, 37) . The structures of CoV M pro s revealed that two CoV M pro molecules form an active homodimer (1, 2, 33, 35) . A Cys-His catalytic dyad is located in a cleft between domains I and II (1, 2, 35) , and the N-terminal residues 1 to 7 (or N finger) of M pro are considered to play an important role in the proteolytic activity (1, 2, 33, 35) . The C-terminal domain III is reported to be required for dimerization (28) .
Here, we report the crystal structures of two CoV M pro s. The first is the IBV M pro structure with a dimeric form and a unique monomeric form in one asymmetric unit. The monomeric form has not been observed in any of the previously reported CoV M pro s; its C terminus inserts into one of the active sites present in the dimer. The second is the structure of an active-site mutant, H41A, of SARS-CoV M pro in complex with the N-terminal 11-amino-acid peptide as the substrate, which provides insights into the substrate binding and specificity of the S1Ј to S5Ј sites in SARS-CoV M pro in an unprecedented way.
As the CoV M pro is responsible for the maturation of itself and the subsequent maturation of the replicase polyproteins (37) , it has become an attractive target for anti-CoV drug design. Here, we also present the cocrystal structure of IBV M pro in complex with N3, a wide-spectrum inhibitor that we designed previously to target CoV M pro s (34) . We further demonstrate its rapid in vitro inactivation against the viral protease and potent antiviral activity toward IBV in chicken embryos. This assay provides an easily accessible animal model for optimizing wide-spectrum inhibitors against CoV-associated diseases. pro -N3 complex and SARS-CoV M pro H41A mutant peptidyl substrate complex were collected at 100°K in house with a Rigaku CuK␣ rotating-anode X-ray generator (MM007) at 40 kV and 20 mA (1.5418 Å) and using a Rigaku R-AXIS IVϩϩ image plate detector. The IBV M pro complex crystal was used directly in data collection without a cryoprotectant. The cryoprotectant solution for the SARS-CoV M pro mutant complex contained 30% PEG400 and 0.1 M Mes (pH 6.0). All data integrations and scaling were performed using HKL2000 (23) . The Matthews coefficient of the new IBV M pro crystal form suggested the existence of three protein molecules per asymmetric unit with an estimated solvent content of 54%.
Structure solution, refinement, and analysis. The IBV M pro structure was solved by the single-wavelength anomalous dispersion method (11) using the diffraction data set collected at the peak wavelength for selenium. The analysis of the selenium positions, performed with the program SHELXD (27) , located all 12 expected selenium sites (four in each protein molecule). Phasing and density modifications subsequently were performed with SOLVE (32) and RESOLVE (31) . The resulting electron density maps were of sufficient quality for chain tracing. Molecular replacement performed with CNS (4) was employed for tracing the typical homodimer (named molecules A and B) into the electron density map using the crystal structure of human CoV-229E (HCoV-229E) M pro as a starting model (Protein Data Bank code 1P9S). The third M pro molecule (named molecule C) was clearly identified in the electron density map, and its tracing was facilitated using the noncrystallographic symmetry of the selenium positions. Cycles of manual adjustment to the model with Coot (8) and subsequent refinement using REFMAC (21) led to a final model with a crystallographic R factor (R cryst ) of 22.7% and a free R factor (R free ) of 25.9% at 2.35-Å resolution.
The IBV M pro -N3 complex structure was determined by the molecular replacement method implemented in CNS using the homodimer (molecules A and B) from the above-described native IBV M pro structure as the search model. Manual adjustments to the model were made with the program O (22) , and subsequent refinement was performed in CNS. Data quality and refinement statistics are summarized in Table 1 .
The structure of the mutant protein (SARS-CoV M pro H41A) in complex with its N-terminal peptide substrate was determined by the molecular replacement method using a SARS-CoV M pro monomer (Protein Data Bank code 1UK2) (35) as a search model. In the complex structure, there are two M pro molecules (named A and B) per asymmetric unit, and it forms a symmetrical homodimer. An 11-mer peptide was identified in molecule A and an 8-mer peptide in molecule B from the initial difference electron density maps. The validation of all final models was carried out with PROCHECK (17) .
In vitro inhibition assays. Proteolytic activity assays of IBV M pro have been described previously (33, 34) . The fluorogenic substrate of SARS-CoV M pro , MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 (Ͼ95% purity; GL Biochem Shanghai Ltd., Shanghai, China), was used to assess the activity of IBV M pro . The excitation and emission wavelengths of the fluorogenic substrate were 320 and 405 nm, respectively. The assay was performed in a buffer of 50 mM Tris-HCl (pH 7.3) and 1 mM EDTA at 30°C, and kinetic parameters were determined by following our previous work (34) .
In ovo inhibition. Titers of the IBV M41 viruses were established as follows. The virus was serially 10-fold diluted in phosphate-buffered saline (PBS) and then inoculated into the allantoic cavity of 10-day-old specific-pathogen-free (SPF) chicken embryos (six embryos per dilution and 0.1 ml virus dilution per embryo). The embryos were incubated at 37°C and were inspected daily. Eight days after inoculation, the eggs were opened and examined to check for typical lesions (including crispature and dwarfism in embryos, yolk sac shrinking, an increase in allantoic fluid, and lithate deposits on the midkidney of embryos) that might signify IBV infection. Six embryos inoculated with PBS were used as negative controls, and another six uninoculated embryos were used as blank controls. The dilution that could cause 50% of embryos to be infected by IBV was calculated using the method described by Reed and Muench (26) and determined as the virus titer (50% egg infectious dose [EID 50 ]).
To assess whether N3 could be used as an anti-IBV preventive agent or a curative agent, two groups of in ovo inhibition experiments were performed. For the curative group, a series of doses of N3 (0.02 to 0.64 mol) was injected into the allantoic cavity of 10-day-old SPF chicken embryos 3 h (for eight embryos; repeated per dose of N3) or 6 h (for six embryos; repeated per dose of N3) after inoculation by a 100-EID 50 titer of IBV M41 virus. For the preventive group, N3 was preinjected into the embryos 3 h (for eight embryos; repeated per dose of N3) or 6 h (six embryos; repeated per dose of N3) prior to the inoculation by a 100-EID 50 titer of virus. Eight days after inoculation, the eggs were opened to check if the embryos were infected by IBV. The inhibitor dose that could protect 50% of embryos from IBV infection was calculated using the method described by Reed and Muench (26) and expressed as the 50% protective dose (PD 50 ).
Meanwhile, a preliminary toxicity assay was performed to assess any potential adverse effects of N3 on the development of chicken embryos. The highest dose of N3 (0.64 mol) dissolved in DMSO was injected into 16 embryos. Sixteen embryos inoculated with DMSO were used as negative controls, while another 16 uninoculated embryos were used as blank controls. Eight days after inoculation, half of the eggs were opened and examined for pathological changes to the organs of the embryos. The remainder of the eggs were continuously incubated at 37°C until the chickens were hatched. All in ovo experiments were performed in a biosafety level 2 bioprotective laboratory. 
RESULTS
Overall structure of native IBV M pro . The IBV M pro crystal structure at a 2.35-Å resolution shows three M pro molecules, named A, B, and C, per asymmetric unit (Fig. 1A) , which is unique among all CoV M pro structures reported to date. While molecules A and B form a typical catalytically active and symmetrical homodimer, molecule C is not involved in such a dimer. Instead, its C terminus inserts into the substrate binding site of molecule A (Fig. 1A) . Molecules A and B are quite similar, with an RMSD (root mean square deviation) of 1.1 Å for all equivalent C␣ atoms, while molecule C is less similar to either A or B, having a mean RMSD of 2.5 Å for the C␣ atoms of residues 6 to 183.
Each IBV M pro molecule is comprised of three domains, I to III (Fig. 1B) . Domains I and II (i.e., residues 3 to 99 and 100 to 182, respectively) have a chymotrypsin-like, two-␤-barrel fold in common with the M pro structures of transmissible gastroenteritis CoV (TGEV), HCoV-229E, and SARS-CoV (1, 2, 35). Domain III (residues 199 to 307) of IBV M pro consists of five ␣ helices that adopt a globular structure apparently unique to CoV M pro . Domains II and III are connected by a loop of residues 183 to 198, which exhibits two distinct conformations in the three M pro molecules. In molecules A and B, it assumes a fairly extended conformation; in molecule C, however, residues 186 to 190 form a short helix (Fig. 1E ). The substrate binding sites are located in the deep cleft between domains I and II, with the catalytic dyad formed by His-41 and Cys-143 at the center of this cleft. Each subunit contains one substrate binding site contributed mainly from itself. Nevertheless, the two monomers swap their N termini to stabilize the S1 pocket in the IBV M pro dimer; similar swapping was also observed in the M pro structures of TGEV, HCoV-229E, and SARS-CoV (1, 2, 19, 33, 35). This arrangement may explain the require- ment of dimerization for the full activity of the M pro proteins (1, 2, 19, 33, 35) .
According to a structure-based sequence alignment (Fig. 2) , there is one deletion and two insertions in IBV M pro not found in the M pro of TGEV and HCoV-229E. The two insertions, namely, residue 70 and residues 216 to 221, all are located in loop regions with unknown functional significance. The threeresidue deletion after Leu-50 makes the corresponding loop (i.e., residues 44 to 50) much tighter than the equivalent region in TGEV and HCoV-229E M pro . The side chain of Lys-45 in this loop is involved in the formation of the S2 pocket, corresponding to Thr-47 in TGEV M pro and HCoV M pro and Met-49 in SARS-CoV M pro . Therefore, the S2 subsite appears to be unique in IBV M pro . Substrate binding sites of IBV M pro . In the IBV M pro structure, the substrate binding pockets of molecule A are occupied by the C terminus (residues 302 to 307, corresponding to the P6 to P1 sites of the M pro substrate) of molecule C ( Fig. 1C and  D) , which forms an antiparallel ␤ sheet with ␤11 (residues 163 to 166) in domain II and with residues 188 to 190 of the linker loop between domains II and III.
In this A-C complex, the S1, S2, and S4 substrate binding sites of molecule A can be clearly recognized (Fig. 1D) . The side chains of Phe-A138, His-A161, Glu-A164, and His-A170 are involved in constituting the S1 subsite, which has an absolute requirement for Gln at the P1 position via two hydrogen bonds (1, 2, 35) . Nevertheless, the side chain of Gln-307 of molecule C does not fit well into the S1 pocket. Instead, its side chain is flipped out from the pocket, probably because the availability of the main chain carboxyl group of Gln in this case (the distance between the carboxyl carbon of Gln-C307 and the sulfur atom of the catalytic Cys-A143 is ϳ3.1 Å). As a result, pro structure. The S1Ј, S2Ј, S1, S2, and S4 subsites are labeled, and the C terminus of molecule C, which occupies the substrate binding sites, is colored magenta. (E) Surface of the substrate binding sites of molecule C in IBV M pro . The S1Ј, S2Ј, and S1 subsites are labeled, and residues 186 to 190, which form a novel helix, also are labeled. the side chain of Gln-P1 is more or less flexible and forms only one hydrogen bond with Glu-A164. The oxyanion hole is not properly formed by Gly-A141, Ala-A142, and Cys-A143, probably due to a disturbance by the flexible Gln, in contrast to the correctly folded oxyanion holes in molecule B. The side chains of His-A41, Lys-A45, Leu-A163, Phe-A179, Asp-A185, and Glu-A187 are involved in forming the deep hydrophobic S2 subsite that is able to accommodate the relatively large side chain of conserved Leu or, in a few cases, Val in the substrates of IBV M pro . As expected, the side chain of Leu-P2 (Leu-C306) is well oriented into the S2 hydrophobic pocket and stabilized by van der Waals interactions. The side chain of Arg-P3 (Arg-C305) is oriented toward bulk solvent but also interacts with the side chain of Glu-164 via van der Waals interactions. The side chains of Leu-A163, Leu-A165, Tyr-A183, and Gln-A190 form the relatively small hydrophobic S4 subsite, which should be able to accommodate small residues such as Val, Ser, Thr, Ala, or Pro. The Gly-P5 and Gly-P6 residues are in faint interactions with the protease. No other interaction is observed between molecule C and molecules A and B from the same asymmetric unit in the IBV M pro crystal structure.
The monomeric form of IBV M pro . Molecule C presents a novel conformation distinct from those of the other two M pro molecules in the IBV M pro structure. The superposition of the first two domains in molecules C and A confirmed that they share similar domain structures (Fig. 3) . However, they bear clear structural differences at the whole-molecule level, mostly due to the conformational change in the linker region connecting the N-terminal two-␤-barrel domains (domains I and II) with the C-terminal ␣-helical domain III. This conformational change includes the formation of a short helix (residues 186 to 190) in this linker region (Fig. 3) , which results in a nearly 5-Å movement of domain III away from domains I and II in molecule C. Differences also occur in the N-and C-terminal conformations between molecules C and A. As described above, the C terminus of molecule C fits well into the substrate binding pocket of molecule A, which was not observed in those of molecules A and B. At the other end, the N terminus of molecule C is flexible and directed away from the surface of domain I; thus, residues 1 to 5 in molecule C could not be traced in the electron density map. In contrast, the N terminus of molecule A inserts into the dimer interface formed by its own domains II and III as well as domain II of the neighboring subunit, where it makes a number of specific interactions to stabilize the dimer structure. This monomer structure of IBV M pro reveals a significant structural flexibility of the linker region connecting domains II and III that has not been reported for other structures of dimeric CoV M pro s to date. The presence of the monomeric form probably was triggered by the binding and fixation of its C terminus in the active site of the M pro dimer, which may preclude dimerization. In the absence of dimerization, the substrate binding sites of molecule C are not well organized. Only the S1, S1Ј, and S2Ј subsites maintain their correct conformations (Fig. 1E) . The S2 and S4 subsites collapse, partly because residues 186 to 190 in the linker region adopt an unusual helical conformation (Fig.  1E) . Nevertheless, the flexibility in the linker region may allow incidental activity in molecule C in the absence of dimerization, which is required for the maturation of M pro . In contrast, in the homodimer form the linker region adopts a conformation to achieve the highest level of proteolytic activity. Overall structure of SARS-CoV M pro H41A mutant in complex with its N-terminal substrate. To further investigate the substrate binding and specificity of CoV M pro , we crystallized an active-site knockout mutant, H41A, of SARS-CoV M pro , soaked the crystals with its natural, N-terminal peptide substrate, and determined the complex crystal structure at a 2.5-Å resolution. There are two M pro molecules per asymmetric unit in this complex structure, named A and B, which form a typical M pro dimer. Both subunits have the same overall structure and almost identical substrate binding modes. An 11-amino-acid peptide in subunit A and an 8-amino-acid peptide in subunit B were identified from difference Fourier electron density maps. The enzyme-bound 11-mer peptidyl substrate essentially is comprised of two parts, the N-terminal residues P6 to P1 and the C-terminal residues P1Ј to P5Ј, which roughly assume conformations of two separate ␤ strands (Fig. 4A) . Similarly to the conformation of the C-terminal residues observed in the IBV M pro crystal structure, residues P6 to P1 form an antiparallel ␤ sheet with residues 164 to 168 on one side and residues 189 to 191 of the linker loop between domains II and III on the other side (Fig. 4B) . The P1Ј to P5Ј strand is located in a groove formed by ␤2 (residues 24 to 27) and the loop of residues 142 to 144 near the catalytic Cys-145 ( Fig. 4A and B) .
Substrate binding sites of SARS-CoV M pro . On the N-terminal side of the substrate, the P6 to P1 positions (Thr-SerAla-Val-Leu-Gln) share a similar binding mode with the previously reported SARS-CoV M pro structures in complex with a variety of Michael acceptor inhibitors (34) . In particular, in the S1 subsite the Gln residue required for high cleavage efficiency seems to intercalate more naturally than the lactam ring in the Michael acceptor inhibitors that we previously designed (34).
FIG. 3. Superposition of the first two domains in molecules C (red)
and A (blue) of the IBV M pro structure. The structures of domains I and II are quite similar. While domains III from the two proteins also are quite similar (with a C␣ RMSD of 0.5 Å), its location in molecule C is transformed away from domains I and II by a conformational change in the long linker region (labeled in the figure) connecting domains II and III.
Two strong hydrogen bonds, between the Oε1 atom of Gln-P1 and the Nε2 atom of His-163 (2.5 Å) and between the Nε2 atom of Gln-P1 and the main chain carbonyl oxygen of Phe-140 (2.8 Å), ensure that the conserved Gln-P1 residue comfortably fits in the S1 pocket (Fig. 4C) . The latter hydrogen bond has not been reported for previous enzyme-inhibitor complex structures. The carbonyl oxygen of Gln-P1 is stabilized by the oxyanion hole formed by the amide groups of Gly-143 and Cys-145 (Fig. 4C) . The P2 to P4 residues bind to the enzyme similarly to the previously reported peptidyl inhibitors (34) . In addition, the Ser-P5 and Thr-P6 residues interact with Pro-168 and Ala-191 of the enzyme through van der Waals interactions.
On the C-terminal side, no structural information for the binding mode of P1Ј to P5Ј residues with M pro has previously been reported. Therefore, the complex structure presented here allows us to explore the substrate binding and specificity of S1Ј to S5Ј in SARS-CoV M pro in an unprecedented way (Fig. 4) . Small residues such as Ser, Gly, and Ala are preferred at the relatively shallow S1Ј subsite, which is composed of Thr-25, Leu-27, Cys-38, Pro-39, Ala-41, Val-42, and Cys-145. The small P1Ј residue directly interacts with the side chains of Thr-25, Leu-27, and Cys-145 via van der Waals interactions. The S2Ј subsite is a narrow but deep pocket composed of residues Thr-26, Asn-28, Tyr-118, Asn-119, and Gly-143. In our complex structure, the S2Ј subsite is occupied by Gly-P2Ј, with additional space occupied by three ordered water molecules (W21, W24, and W80). The hydrophilic S2Ј pocket can accommodate a long side chain residue at the P2Ј position, such as the lysine residue at the corresponding site for its C-terminal autocleavage. The main-chain amide and the carbonyl oxygen of Gly-P2Ј form a pair of hydrogen bonds with the main-chain atoms of Thr-26 (Fig. 4C) . The P3Ј side chain appears to point toward the solvent and makes no specific interactions with the protease. The Arg-P4Ј residue also is stabilized by two hydrogen bonds: one occupies 3.1 Å between the amide group of Arg-P4Ј and the carbonyl oxygen of Thr-24, and the other occupies 2.9 Å between the N1 atom of Arg-P4Ј and the Nε2 atom of Gln-69. The complex structure shows that the P5Ј residue has little interaction with the protease.
Active-site comparison between IBV M pro and SARS-CoV M pro . Since the substrate-bound structures of both IBV M pro and SARS-CoV M pro became available from this study, we compared the conformations of the active sites in these two structures (Fig. 5) . In the S1 subsite, the outer wall made up of residues 141 to 143 in the SARS-CoV M pro structure is not present in the IBV M pro structure, possibly due to the disturbance of Gln-P1 (Gln-C307). Ala-140 of IBV M pro is away from the active site, so that the S1 pocket is larger than that in SARS-CoV M pro . Lys-45 and Glu-187 in IBV M pro , instead of Met-49 and Glu-189 in SARS-CoV M pro , form the outer wall of the S2 subsite (Fig. 1D) . Lys-45 of IBV M pro moves ϳ2 Å away from the S2 subsite, such that the S2 pocket in IBV M pro is slightly larger than that in SARS-CoV M pro . The P3 position of IBV M pro is occupied by an arginine residue with a long side chain, which makes interactions with the side chains of Glu-164 and Arg-B305. It seems likely that a longer side chain is preferred to stabilize the substrate binding site here and that the modification of the P3 position may be a good choice for the design of substrate-based inhibitors targeting CoV M pro . The S1Ј and S2Ј subsites are quite similar in both M pro structures, implying substrate conservation on the two subsites, which also may be applicable for inhibitor design. Structure of IBV M pro in complex with inhibitor N3. We have previously designed a series of broad-spectrum inhibitors targeting CoV M pro (34) . Of these inhibitors, a Michael acceptor inhibitor named N3 strongly inhibits the replication of SARS-CoV, TGEV, HCoV-229E, mouse hepatitis virus A59, and feline infectious peritonitis virus in cell-based assays (34) . In this study, the cocrystallization of N3 with IBV M pro yielded high-quality crystals. The subsequent high-resolution structure of IBV M pro in complex with N3 together with the in vitro inhibition assay results (shown in Table 2) reveal that N3 could block the activity of the M pro through a standard Michael addition reaction.
Unlike the native structure, the complex structure of IBV M pro with the inhibitor N3 has a homodimer in each asymmetric unit. Each dimer has approximate C 2 symmetry, which is consistent with other M pro -inhibitor complex structures we have solved to date (33, 34) . From the omit electron density map, clear electron density was identified for N3 bound in the substrate binding pocket (Fig. 6B and C) . Residues P3 to P5 form a typical antiparallel ␤ sheet with residues 163 to 166 of the ␤11 strand on one side, while on the other side they interact with residues 187 to 189 of the loop linking domains II and III.
In the inhibitor-bound complex structure, the S ␥ atom of the nucleophilic Cys-143 forms a clear 1.9-Å C-S covalent bond with the C ␤ atom of the vinyl group, which is a typical Michael addition (Fig. 6B) . The fact that Michael acceptor inhibitors can irreversibly react with the active site of the enzyme makes N3 a standard suicide inhibitor. We have previously reported the crystal structure of SARS-CoV M pro in complex with N3 (33, 34), so we superimposed the substrate binding pockets of the IBV M pro -N3 and SARS-CoV M pro -N3 complex structures. A comparison of the two inhibitor-bound complex structures implies a similar binding mode of this Michael acceptor inhibitor (Fig. 6D) . The largest difference between the two complex structures occurs, however, in the orientation of the benzyl ester group. The side chain of Asn-142 in the SARSCoV M pro complex structure disturbs the comfortable orientation of the benzyl ester at the P1Ј site. In the corresponding position of IBV M pro , Asn-142 is replaced with Ala-140, and the benzyl ester points toward the solvent in a much more comfortable orientation. Another significant difference lies in the S2 site, where Lys-45 in the IBV M pro complex structure is replaced by Met-49 in the SARS-CoV M pro complex structure. In ovo inhibition of IBV by N3. An in ovo inhibition assay in chicken embryos was performed to further substantiate the effects of N3 on IBV inhibition. One method used was the neutralization test in chicken embryos, which was implemented to assess the neutralizing power of an antiserum or inhibitor against pathogens such as viruses (6) . Infection by the IBV M41 strain was identified by the presence of typical lesions (as described in Materials and Methods). Firstly, the virus titer (EID 50 ) of this IBV M41 strain was determined as 0.1 ml, a 10 Ϫ6.5 dilution of viruses. To assess the stage of infection at which the inhibitor can be used effectively, a series of doses of N3 was used as curative agents and introduced into the chicken embryos 3 h (Fig. 7A) or 6 h (Fig. 7B) following inoculation with a 100-EID 50 titer of IBV M41 virus. The dose-response data show that N3 is able to penetrate cells to inhibit the replication of IBV viruses, probably at the beginning of infection ( Fig. 7A and B) . The PD 50 of N3 was calculated as 0.13 mol for the 3-h group and 0.17 mol for the 6-h group according to the method described by Reed and Muench (26) . These inhibition data further imply that the earlier N3 is used during infection, the more effective is the inhibition of the IBV virus. For instance, a 0.08-mol dose of N3 per embryo introduced 3 h after inoculation could protect ϳ40% of chicken embryos not infected by the IBV M41 virus, while it could protect no chicken embryos when introduced 6 h after inoculation. However, a 0.64-mol dose of N3 per embryo introduced either 3 or 6 h after inoculation could protect, in both cases, all chicken embryos from infection.
To verify whether N3 could be used as an anti-IBV preventive agent, another group of experiments was performed. A series of doses of N3 was introduced into the chicken embryos 3 h (Fig. 7C ) or 6 h (Fig. 7D) prior to virus inoculation. The PD 50 of N3 for this preventative group was calculated as 0.099 mol for the 3-h group and 0.095 mol for the 6-h group. Therefore, consistently with the antiviral activity of N3 in vitro, our results show better inhibition of IBV with N3 used as a preventive agent than as a curative agent.
Meanwhile, in the preliminary toxicity assay of N3 on chicken embryos, half of the eggs from the three groups (0.64-mol N3 control group, DMSO-negative control group, and blank control group) were opened and examined 8 days after inoculation. No significant pathological changes or lesions were found in the shape and organs of chicken embryos. The remaining eggs from the three groups then were hatched, and no significant differences were found in the baby chickens physically or spiritually. Thus, the toxicity assay for N3 signifies that even a 0.64-mol dose of N3 per embryo has no detectable negative impact on the development of the chicken embryos.
Further improvements on inhibitor design. The substratebound structures of IBV M pro and SARS-CoV M pro provide useful information for antiviral drug design. Taking the framework of N3 as a starting point, we designed another series of Michael acceptor inhibitors and measured their inhibition activities against SARS-CoV M pro and IBV M pro . Two of these new inhibitors, named N27 and H16 (Fig. 6A ), which were synthesized by the State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China, have a relatively large side chain at the P3 position and show 
DISCUSSION
In this study, we analyzed the structures of native IBV M pro and a SARS-CoV M pro active-site mutant, H41A, in complex with its N-terminal peptide substrate. First, in the structure of IBV M pro , there are three crystallographically independent M pro molecules. Two of them form a symmetric, catalytically active homodimer with two identical but independent active sites. The other M pro molecule is identified with its C-terminal autocleavage residues inserted into one of the substrate binding sites of the catalytic dimer. Second, the substrate-bound structure of the SARS-CoV M pro mutant offers novel, detailed information on the binding pattern of the P6 to P5Ј sites. For example, the main chain of the P6 to P1 ␤ strand is at an angle of ϳ125°to the P1Ј to P5Ј strand around the P1 to P1Ј site, which probably facilitates the specific cleavage at this site.
A comparison of the substrate binding sites in the two M pro structures provides structural insights for the design of substrate-based inhibitors targeting CoV M pro s. The conservation at the S1Ј and S2Ј subsites in the two structures has prompted us to design a new generation of inhibitors with, for example, a small P1Ј residue and a long hydrophilic P2Ј side chain. Furthermore, at the substrate binding site of molecule A in IBV M pro , the orientation of the long side chain of Arg-P3 (Arg-C305) is in accordance with that of Glu-A164, which would stabilize the substrate (or inhibitor) binding at this position via a van der Waals interaction between these two residues (Fig. 1C) . The interaction discussed above suggests that the modification of the P3 position with a relatively long side chain potentially is beneficial for inhibitor-M pro binding. This notion is strongly supported by the observation that N27 and H16 inhibitors, both of which have a larger side chain than N3 at the P3 position, show significantly improved inhibition ability against SARS-CoV M pro . Moreover, the S2 subsite in IBV pro . In addition, according to the native IBV M pro structure, the monomeric form of M pro reveals significant structural flexibility in the interdomain linker region, which may allow incidental activity during CoV M pro maturation. Thus, locking the loop region into a certain conformation may provide a new strategy to block the activity of CoV polyprotein.
In addition to the above-described two structures that show specific substrate/product binding of CoV M pro s, we also characterized the inhibitor-bound structure of IBV M pro , which shares a similar binding mode with the previously reported M pro structures in complex with Michael acceptor inhibitors. The in ovo inhibition assay performed in chicken embryos, together with the in vitro inhibition assay, provides evidence that N3 can block IBV replication via inhibition of the M pro , the key enzyme in the viral replication cycle. N3 shows a high level of inhibitory efficiency, as our results indicate that a 0.64-mol (or 44-g) dose of inhibitor per embryo is sufficient to effectively prevent infection by IBV. As reported previously, the Michael acceptor inhibitors are wide-spectrum inhibitors against all CoV-associated diseases. Hence, the in ovo inhibition assay reported here provides a feasible approach for the discovery of anti-SARS drug candidates, which is important considering the high risk to human health posed by SARS-CoV.
